BR9711319A - Derivados de camptotecina altamente lipofìlicos. - Google Patents

Derivados de camptotecina altamente lipofìlicos.

Info

Publication number
BR9711319A
BR9711319A BR9711319-0A BR9711319A BR9711319A BR 9711319 A BR9711319 A BR 9711319A BR 9711319 A BR9711319 A BR 9711319A BR 9711319 A BR9711319 A BR 9711319A
Authority
BR
Brazil
Prior art keywords
compounds
highly lipophilic
camptothecin derivatives
lipophilic camptothecin
camptothecin
Prior art date
Application number
BR9711319-0A
Other languages
English (en)
Other versions
BR9711319B1 (pt
Inventor
Frederick Herman Hausheer
Kochat Haridas
Peddaiahgari Seetharamalu
Dhanabalan Murali
Dasharata Gauravaram Reddy
Shijie Yao
Pavankumar Petluru
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Publication of BR9711319A publication Critical patent/BR9711319A/pt
Publication of BR9711319B1 publication Critical patent/BR9711319B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)

Abstract

"DERIVADOS DE CAMPTOTECINA ALTAMENTE LIPOFìLICOS", compreendendo compostos de acordo com a fórmula (I), onde R~ 1~ é acila de fórmula -C(O)R~ 2~, onde R" 2" é alquila C~ 1-6~, alquenila C~ 2-6~, alquinila C~ 2-6~, ou arila; ou R~ 1~ é alquenila C~ 2-8~ ou alquinila C~ 2-8~, sendo cada uma opcionalmente substituída por um ou mais átomos halogênios, grupos hidroxila, alquila C~ 1-6~ ou grupos alcóxi C~ 1-6~; ou R~ 1~ é halo; oxo, caso no qual as ligações duplas 1,2- e 6,7 no anel são substituídas por uma única ligação dupla 2,6- no anel; ou -S-R~ 3~, onde R~ 3~ é alquila C~ 1-6~, arila ou halo- ou arila substituída por alquila C~ 1-6~; ou R~ 1~ é alquila -S(O)-C~ 1-6~; -OSO~ 2~CF~ 3~; ou -SiR~ 8~R~ 9~R~ 10~, -R~ 5~-SiR~ 8~R~ 9~R~ 10~ ou -S-R~ 5~-SiR~ 8~R~ 9~R~ 10~, onde R~ 5~ é alquileno C~ 1-6~, alquenileno C~ 2-6~ ou alquinileno C~ 2-6~ e cada um dos radicais R~ 8~, R~ 9~ e R~ 10~ é individualmente hidrogênio ou alquina C~ 1-6~; e R~ 11~ é hidrogênio, hidroxila ou um grupo de proteção ou hidroxila que protege o grupo hidroxila contra a triflilação; na forma das bases livres ou seus sais de adição de ácido farmaceuticamente aceitáveis são altamente lipofílicos, estáveis em lactona, não requerem ativação metabólica e são compostos anti-neoplásicos.
BRPI9711319-0A 1996-08-19 1997-08-15 derivados de camptotecina altamente lipofìlicos. BR9711319B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2417196P 1996-08-19 1996-08-19
PCT/GB1997/002205 WO1998007727A1 (en) 1996-08-19 1997-08-15 Highly lipophilic camptothecin derivatives

Publications (2)

Publication Number Publication Date
BR9711319A true BR9711319A (pt) 2000-01-18
BR9711319B1 BR9711319B1 (pt) 2009-08-11

Family

ID=21819224

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9711319-0A BR9711319B1 (pt) 1996-08-19 1997-08-15 derivados de camptotecina altamente lipofìlicos.

Country Status (17)

Country Link
US (3) US5910491A (pt)
EP (1) EP0925301B1 (pt)
JP (1) JP4364305B2 (pt)
KR (1) KR100516593B1 (pt)
CN (1) CN1107678C (pt)
AT (1) ATE261974T1 (pt)
AU (1) AU718799C (pt)
BR (1) BR9711319B1 (pt)
CA (1) CA2262745C (pt)
DE (1) DE69728152T2 (pt)
DK (1) DK0925301T3 (pt)
ES (1) ES2214634T3 (pt)
IL (1) IL127800A (pt)
NZ (1) NZ334240A (pt)
PT (1) PT925301E (pt)
WO (1) WO1998007727A1 (pt)
ZA (1) ZA977437B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150343A (en) * 1993-06-30 2000-11-21 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6743917B2 (en) 1993-06-30 2004-06-01 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6136978A (en) 1993-06-30 2000-10-24 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
FR2790261B1 (fr) * 1999-02-26 2004-09-10 Sod Conseils Rech Applic Nouveaux analogues optiquement purs de la camptothecine et leurs procedes de preparation
US6407118B1 (en) * 1996-01-30 2002-06-18 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
AU718799C (en) * 1996-08-19 2004-02-12 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6169080B1 (en) * 1997-02-13 2001-01-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6057303A (en) * 1998-10-20 2000-05-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic Camptothecin derivatives
DE69901379T2 (de) * 1999-03-09 2002-11-07 Sigma Tau Ind Farmaceuti Camptothecin-Derivate mit Antitumor-Wirkung
US7105492B2 (en) 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
US6207832B1 (en) 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
WO2000066127A1 (en) * 1999-05-04 2000-11-09 Bionumerik Pharmaceuticals, Inc. Novel highly lipophilic camptothecin analogs
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7332550B2 (en) * 2000-10-06 2008-02-19 Carnegie Mellon University Stabilization of transition metal complexes for catalysis in diverse environments
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6372906B1 (en) 2001-04-12 2002-04-16 University Of Pittsburgh Synthesis of silyl camptothecins and silyl homocamptothecins
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US6723853B2 (en) 2001-08-27 2004-04-20 University Of Pittsburgh Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins
WO2003101406A1 (en) * 2002-06-03 2003-12-11 California Pacific Medical Center Homo-camptothecin derivatives
AU2003243380A1 (en) * 2002-06-03 2003-12-19 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
US6723849B1 (en) * 2002-10-25 2004-04-20 Bionumerik Pharmaceuticals, Inc. Process for making camptothecin derivatives
US7067666B2 (en) * 2003-06-27 2006-06-27 Research Triangle Institute 7-substituted camptothecin and camptothecin analogs and methods for producing the same
WO2005060871A1 (en) * 2003-12-17 2005-07-07 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
ATE518870T1 (de) * 2003-12-17 2011-08-15 Bionumerik Pharmaceuticals Inc Verfahren zur herstellung von camptothecin- derivaten
US7030243B1 (en) 2004-10-28 2006-04-18 Bionumerik Pharmaceuticals, Inc. Process for making camptothecin derivatives
US20060094692A1 (en) * 2004-10-28 2006-05-04 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of camptothecins and process for making same
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
EP2007386B1 (en) * 2006-04-19 2012-08-22 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, flipped lactone-stable, e-ring and methods for making and using same
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
CN101652150B (zh) * 2006-12-01 2013-12-11 韦克福里斯特大学健康科学院 结合胶原抑制剂的医疗装置
EP2197879B1 (en) * 2007-10-16 2014-01-22 Bionumerik Pharmaceuticals, Inc. C7-substituted camptothecin analogs
CA2700904C (en) * 2007-10-16 2014-10-14 Bionumerik Pharmaceuticals, Inc. C10-substituted camptothecin analogs
US7687496B2 (en) 2007-10-16 2010-03-30 Bionumerik Pharmaceuticals, Inc. C7-substituted camptothecin analogs
US7687497B2 (en) 2007-10-16 2010-03-30 Bionumerik Pharmaceuticals, Inc. C10-substituted camptothecin analogs
US20140073793A1 (en) * 2012-09-07 2014-03-13 BioNumeric Pharmaceuticals, Inc. Germanium-containing camptothecin analogues
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
DE2150234A1 (de) * 1971-10-08 1973-04-12 Basf Ag Verfahren zur herstellung von camptothecin und camptothecin-derivaten
DE2534601A1 (de) * 1975-08-02 1977-02-17 Basf Ag Verfahren zur herstellung von camptothecin-aehnlichen verbindungen
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US5405963A (en) * 1993-06-10 1995-04-11 Smithkline Beecham Corporation Process for asymmetric total synthesis of camptothecin analogues
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
AU718799C (en) * 1996-08-19 2004-02-12 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives

Also Published As

Publication number Publication date
ZA977437B (en) 1999-02-19
PT925301E (pt) 2004-08-31
ES2214634T3 (es) 2004-09-16
EP0925301A1 (en) 1999-06-30
BR9711319B1 (pt) 2009-08-11
DE69728152D1 (en) 2004-04-22
AU4020497A (en) 1998-03-06
IL127800A (en) 2005-11-20
DK0925301T3 (da) 2004-07-12
JP4364305B2 (ja) 2009-11-18
NZ334240A (en) 2000-01-28
CN1227559A (zh) 1999-09-01
CA2262745C (en) 2006-04-04
JP2000516933A (ja) 2000-12-19
DE69728152T2 (de) 2004-08-05
KR100516593B1 (ko) 2005-09-22
IL127800A0 (en) 1999-10-28
CA2262745A1 (en) 1998-02-26
WO1998007727A1 (en) 1998-02-26
AU718799B2 (en) 2000-04-20
AU718799C (en) 2004-02-12
KR20000068135A (ko) 2000-11-25
US6028078A (en) 2000-02-22
US5910491A (en) 1999-06-08
ATE261974T1 (de) 2004-04-15
CN1107678C (zh) 2003-05-07
US6194579B1 (en) 2001-02-27
EP0925301B1 (en) 2004-03-17

Similar Documents

Publication Publication Date Title
BR9711319A (pt) Derivados de camptotecina altamente lipofìlicos.
ATE329903T1 (de) Hochgradig lipophile camptothecin-derivate
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
TR200200717T2 (tr) Terapötik kinazolin türevleri.
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
AR028948A1 (es) Compuestos novedosos
GB0022438D0 (en) Organic Compounds
PT1200412E (pt) Agentes anti-proliferativos de imidazole
PA8481301A1 (es) Derivados de 4,4-biarilpiperidina
SE9904508D0 (sv) New compounds
DE60001974D1 (de) Derivate von flavonen, xanthonen und kumarinen
CY1106726T1 (el) Υποκατεστημενα βενζοπυρανια ως επιλεκτικοι συναγωνιστες οιστρογονικου υποδοχεα β
MX9307011A (es) Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE297904T1 (de) Halo-alkoxycarbonylverbindungen
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
PT1109560E (pt) Compostos uteis como inidores de aicarft
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
EE200200681A (et) Akrüloüüldistamütsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritudravimpreparaat
BR0014687A (pt) Compostos de taxano pentacìclico
DE60005334D1 (de) 6-o-carbamat ketolide derivate
SE9803107D0 (sv) Novel Compunds
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/09/2009, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: BIONUMERIK PHARMACEUTICALS, INC. (US)

B25A Requested transfer of rights approved

Owner name: CROWN BIOSCIENCE, INC. (US)

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22.09.2019